Table 2.
Laboratory, radiologic and microbiological findings
| Variable | Value (n and %) |
|---|---|
| Laboratory | |
| Urine sediment | |
| Pyuria, n (%) | 7 (25.9%) |
| Microscopic hematuria, n (%) | 3 (11.1%) |
| Blood tests | |
| Hemoglobin in g/dL, mean (SD) | 10.1 (SD 1.5) |
| Serum creatinine in mg/dL, mean (SD) | 1.5 (SD 1.2) |
| Estimated GFR in mL/min, mean (SD) | 62.01 (SD 27.39) |
| WBC count per microliter, mean (SD) | 12,508.1 (SD 4350.1) |
| CT findings (M&E classification) | |
| Malek 1 | 10 (37%) |
| Malek 2 | 8 (29.6%) |
| Malek 3 | 8 (29.6%) |
| Psoas abscess | 3 (11.1%) |
| Positive urine culture | 13 (48.1%) |
| Proteus mirabilis | 5 (18.5%) |
| Escherichia coli | 4 (14.8%) |
| Pseudomonas aeruginosa | 2 (7.4%) |
| Mixed | |
| E. coli + Streptococcus constellatus | 1 (3.7%) |
| P. mirabilis + Serratia marcescens | 1 (3.7%) |
| Prescribed antibiotics | |
| Piperacillin/tazobactam (TZP) | 13 (48.1%) |
| Ceftriaxone | 5 (18.5%) |
| Amoxicillin/clavulanic acid | 3 (11.1%) |
| Others | 6 (21.9%) |
| Overall antibiotic resistance profile (%) | |
| Quinolones | 14.30% |
| Carbapenems | 0% |
| Amoxicillin/clavulanic acid | 12.50% |
| Piperacillin/tazobactam (TZP) | 14.30% |
| Ceftriaxone | 16.60% |
| Fosfomycin | 33.30% |
| Trimethoprim/sulfamethoxazole (TMP/SMX) | 33.30% |
GFR: glomerular filtration rate